US2018250282A1PendingUtilityA1

Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1

Assignee: LILLY CO ELIPriority: Oct 29, 2014Filed: May 7, 2018Published: Sep 6, 2018
Est. expiryOct 29, 2034(~8.3 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61P 19/02A61P 19/00A61K 31/00C07D 401/04A61K 31/4709C07D 211/62A61K 31/451C07D 405/14C07D 211/00A61K 31/506A61K 31/4725A61K 31/4545
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salt thereof, where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.

Claims

exact text as granted — not AI-modified
1 - 23 . (canceled) 
     
     
         24 . A method of treating a patient in need of treatment for pain or inflammation associated with arthritis or osteoarthritis said method comprising administering to the patient an effective amount of 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, in combination with an effective amount of a second agent selected from the group consisting of ibuprofen, aspirin, acetaminophen, celecoxib, naproxen, and ketoprofen.

Join the waitlist — get patent alerts

Track US2018250282A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.